Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 452 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Locations: - USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
- Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona
+ 41 more sites in the U.S.
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- University of California, Fresno — Clovis, California
- University of California, San Diego — La Jolla, California
+ 39 more sites in the U.S.
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Locations: - Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
- Southern VA Health Care System /ID# 266254 — Tucson, Arizona
- UCSF FRESNO/Community Cancer Institute /ID# 270874 — Clovis, California
+ 29 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Locations: - Keck School of Medicine of USC — Los Angeles, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
- Yale University — New Haven, Connecticut
+ 21 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Locations: - GC2202 Study Site 115 — Huntington Park, California
- GC2202 Study Site 103 — St. Petersburg, Florida
- GC2202 Study Site 111 — Bethesda, Maryland
+ 4 more sites in the U.S.
Phase 3 Recruiting Industry
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Locations: - Quetzal Site 1 — Duarte, California
- Quetzal Site 7 — Los Angeles, California
- Quetzal Site 5 — Stanford, California
+ 4 more sites in the U.S.
Phase 3 Recruiting Industry
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once ever…
Sponsor: Grifols Biologicals, LLC
NCT ID: NCT07582432
Locations: - Study Site 102 — St. Petersburg, Florida
- Study Site 101 — Fort Wayne, Indiana
- Study Site 105 — Westbrook, Maine
+ 2 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) …
Sponsor: BeOne Medicines
NCT ID: NCT07277231
Locations: - Stanford Cancer Institute — Palo Alto, California
- Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 3 Recruiting Academic/Other
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and a…
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT ID: NCT07223814
Locations: - US-Cincinnati OH-CINCY — Cincinnati, Ohio
Phase 2, Phase 3 Recruiting Academic/Other
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemot…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04708054
Locations: - M D Anderson Cancer Center — Houston, Texas